Co-Crystal Formation in Formulation Development: Merck Case Study
Add bookmark
With the latest publications from the FDA causing controversy across the industry and brand new scale up success stories highlighted in multiple publications, co-crystals reamains a hot topic in formulation. Axel Becker, Scientist from Merck, gives Pharma IQ an industry insight into differences between desired vs accidental co-crystal formation and solid-state conversion aspects in formulation development.
[inlinead]
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
Tags:
Co-crystal formation
Merck
Pharma co-crystals
Solubility enhancement
Co-Crystal fda regulation
